P2P review · CGRP receptor antagonist
Erenumab (Aimovig) P2P review prep
CGRP receptor antagonist. Indications: Migraine prevention
Drug class
CGRP receptor antagonist
Payer criteria typically applied
- ≥4 monthly migraine days
- Failed ≥2 preventive trials
Common medical director objections
- Preventive failures not documented
- Migraine days count
Pitfalls to avoid
- Trial documentation required
Frequently asked questions
What does the payer typically require for Erenumab (Aimovig)?
≥4 monthly migraine days; Failed ≥2 preventive trials.
What objections does the medical director typically raise?
Preventive failures not documented; Migraine days count.
What pitfalls should I avoid during the P2P call?
Trial documentation required.
Sources
Prep Erenumab (Aimovig) P2Ps faster — try ApprovalHelp free
ApprovalHelp auto-prepares P2P talking points from the patient's chart, surfaces payer-specific objections, and generates the post-call appeal draft. no setup fee.
Get started →Contact: hello@approvalhelp.com